Publications by authors named "T Tomomatsu"
Article Synopsis
- Perioperative FEC therapy is a common treatment for breast cancer, but over 20% of patients experience febrile neutropenia (FN), which pegfilgrastim is often used to prevent.
- A study on pegfilgrastim's long-term safety found no significant differences in blood cell counts or long-term effects after one year of use.
- Pegfilgrastim administration significantly reduced the incidence of FN (6.5% with pegfilgrastim vs. 22.8% without), indicating it can be safely used for one year in breast cancer patients undergoing chemotherapy.
Article Synopsis
- A study investigated the costs and survival outcomes associated with pegfilgrastim prophylaxis for febrile neutropenia (FN) in breast cancer patients undergoing chemotherapy in Japan.
- The pegfilgrastim group had higher median total medical costs compared to the non-pegfilgrastim group but did not show a significant difference in FN hospitalization costs.
- Despite increased costs, there was no significant difference in 3-year overall survival rates between the two groups, suggesting pegfilgrastim should be used selectively based on individual FN risk factors rather than routinely.
Background: Female sex and younger age are reported risk factors for chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy, but the underlying mechanism has not been elucidated. The purpose of this study was to clarify the impact of menopause on CINV.
Methods: This retrospective observational study analyzed data from consecutive patients who received their first cycle of perioperative anthracycline-based chemotherapy for breast cancer between January 2018 and June 2020.
Background: Real-time phase mapping (ExTRa™) is useful in determining the strategy of catheter ablation for non-paroxysmal atrial fibrillation (AF). This study aimed to investigate the features of drivers of AF associated with its termination during ablation.
Methods: Thirty-six patients who underwent catheter ablation for non-paroxysmal AF using online real-time phase mapping (ExTRa™) were enrolled.
Article Synopsis
- The study examined how coexisting sick sinus syndrome (SSS) affects the success of catheter ablation (CA) in treating atrial fibrillation (AF) through a large-scale registry involving over 5,000 patients.
- Findings showed no significant differences in AF-free survival rates between patients with SSS and those without, indicating that SSS does not negatively impact the effectiveness of CA.
- Although 48 patients with SSS needed pacemakers, which correlated with AF recurrence, the majority (85.3%) did not require one within three years post-ablation, suggesting that most patients with SSS can have successful outcomes.